ECSP066873A - Compuestos hmb y usos parecidos - Google Patents
Compuestos hmb y usos parecidosInfo
- Publication number
- ECSP066873A ECSP066873A EC2006006873A ECSP066873A ECSP066873A EC SP066873 A ECSP066873 A EC SP066873A EC 2006006873 A EC2006006873 A EC 2006006873A EC SP066873 A ECSP066873 A EC SP066873A EC SP066873 A ECSP066873 A EC SP066873A
- Authority
- EC
- Ecuador
- Prior art keywords
- patient
- hmb
- present
- administration
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 238000012512 characterization method Methods 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229940024606 amino acid Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
Abstract
La presente invención tiene relación con los procedimientos para la prevención y tratamiento de enfermedades inflamatorias crónicas, cáncer y pérdida involuntaria de peso. En la práctica de la presente invención, a los pacientes se les administra por vía enteral HMB sólo o alternativamente en combinación con eicosapentanóico (20:5 ?-3), FOS, carnitina y mezclas parecidas.En otra caracterización, la presente invención provee un procedimiento para el tratamiento del enflaquecimiento de un paciente asociado con una enfermedad. El procedimiento comprende la administración al paciente de la composición arriba descrita, que contiene HMB en cantidades suficientes para tratar el desgaste asociado con la enfermedad, en el cual, con la administración del compuesto al paciente se trata el desgaste asociado con la enfermedad. En otra caracterización, la presente invención provee un procedimiento para reducir la tasa de crecimiento del tumor en un paciente. El procedimiento consiste en la administración a un paciente el compuesto arriba descrito, que contiene HMB en cantidad suficiente para reducir la tasa de crecimiento del tumor, en el cual, luego de la administración la tasa de crecimiento del tumor es reducida.En otra caracterización, la presente invención provee un procedimiento para la prevención o tratamiento de la enfermedad en pacientes, reduciendo la regulación de la expresión y/o actividad de la proteína kinasa C, el factor nuclear kappa-B, enzimas que conjugan ubiquitina y componentes de proteasoma 26S. Estos procedimientos consisten en la administración a un paciente de HMB, sales, metabolitos o derivados parecidos. Todavía en otra caracterización, el HMB puede ser agregado a productos alimenticios que contienen una fuente de amino-nitrógeno enriquecida con grandes aminoácidos neutros como la leucina, isoleucina, valina, tirosina, treonina y fenilalanina y sustancialmente carente de aminoácidos libres.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/810,762 US20050215640A1 (en) | 2004-03-26 | 2004-03-26 | HMB compositions and uses thereof |
| PCT/US2005/007951 WO2005102301A2 (en) | 2004-03-26 | 2005-03-14 | Hydroxymethylbutyrate compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066873A true ECSP066873A (es) | 2006-11-24 |
Family
ID=34990887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006873A ECSP066873A (es) | 2004-03-26 | 2006-09-22 | Compuestos hmb y usos parecidos |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US20050215640A1 (es) |
| EP (3) | EP2301529B1 (es) |
| JP (3) | JP5145033B2 (es) |
| KR (2) | KR101253063B1 (es) |
| CN (1) | CN101212961A (es) |
| AU (1) | AU2005235133B2 (es) |
| BR (1) | BRPI0509017A (es) |
| CA (2) | CA2807787C (es) |
| EC (1) | ECSP066873A (es) |
| ES (2) | ES2699161T3 (es) |
| IL (1) | IL178039A0 (es) |
| MX (1) | MXPA06010922A (es) |
| TW (1) | TWI369981B (es) |
| WO (1) | WO2005102301A2 (es) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| PL371081A1 (pl) * | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| ES2548432T3 (es) * | 2005-12-19 | 2015-10-16 | Abbott Laboratories | Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2 |
| US9358242B2 (en) | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
| US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
| US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| CA2984935C (en) | 2009-02-24 | 2021-01-12 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| MX377553B (es) | 2009-04-29 | 2025-03-10 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| BRPI1011883A2 (pt) | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| CN101704736A (zh) * | 2009-10-30 | 2010-05-12 | 黄再新 | β-羟基-β-甲基丁酸生产过程中氯气逸出时的应急处理方法 |
| US8335592B2 (en) | 2009-11-24 | 2012-12-18 | Pepsico, Inc. | Beverage dispensing device |
| US9754437B2 (en) * | 2009-11-24 | 2017-09-05 | Pepsico, Inc. | Automated beverage formulation |
| US8490829B2 (en) | 2009-11-24 | 2013-07-23 | Pepsico, Inc. | Personalized beverage dispensing device |
| ES2608483T3 (es) * | 2009-12-18 | 2017-04-11 | Metabolic Technologies, Inc. | Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB) |
| BR112012018642A2 (pt) * | 2010-01-29 | 2015-09-01 | Abbott Lab | Pos nutricionais compreendendo hmb seco por pulverizacao |
| WO2011094551A1 (en) * | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Plastic packaged nutritonal liquids comprising hmb |
| SG182812A1 (en) * | 2010-01-29 | 2012-09-27 | Abbott Lab | Nutritional emulsions comprising calcium hmb |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| TWI519242B (zh) * | 2010-01-29 | 2016-02-01 | 亞培公司 | 包含鈣hmb及可溶性蛋白質的營養乳劑 |
| WO2011094548A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
| WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| TWI526161B (zh) * | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
| EP2444083A1 (en) * | 2010-10-21 | 2012-04-25 | Nestec S.A. | Cysteine and food intake |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| CN103338658A (zh) * | 2010-12-22 | 2013-10-02 | 雅培制药有限公司 | 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品 |
| EP2658535A1 (en) * | 2010-12-27 | 2013-11-06 | Abbott Laboratories | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| EP2672843B1 (en) * | 2011-02-07 | 2018-07-11 | Abbott Laboratories | Nutritional products comprising beta-hydroxy-beta-methylbutyrate |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US9326956B2 (en) | 2011-02-17 | 2016-05-03 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate |
| PH12013501773A1 (en) * | 2011-03-31 | 2013-10-14 | Nestec Sa | Nutritional compositions for increasing arginine levels and methods of using same |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| CA2846041A1 (en) * | 2011-08-15 | 2013-02-21 | Yao-En Li | Process for manufacturing hmb and salts thereof |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| ES2421187B1 (es) * | 2012-02-23 | 2014-11-26 | Abbott Laboratories | Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato |
| US20150119339A1 (en) * | 2012-06-11 | 2015-04-30 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
| US9603826B2 (en) | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20140037813A1 (en) * | 2012-08-02 | 2014-02-06 | Mead Johnson Nutrition Company | Nutritional creamer composition |
| BR112015005199B1 (pt) * | 2012-09-10 | 2022-09-06 | Metabolic Technologies, Inc | Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo |
| MX2015003498A (es) * | 2012-09-17 | 2015-06-04 | Abbott Lab | Composiciones que contienen acido beta-hidroxi-beta-metilbutirico y usos de las mismas. |
| EP2897472A1 (en) | 2012-09-21 | 2015-07-29 | Abbott Laboratories | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| JP2016505023A (ja) * | 2013-01-15 | 2016-02-18 | ニューサート サイエンシーズ, インコーポレイテッド | 肺の状態の処置 |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| AU2014225786B2 (en) | 2013-03-08 | 2017-10-12 | Axiom Foods, Inc. | Rice protein supplements |
| WO2014152606A2 (en) | 2013-03-14 | 2014-09-25 | Abbott Laboratories | Treatment of insulin resistance associated with prolonged physical inactivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150057350A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Fibrosis biomarkers and methods of using same |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| JP6349575B2 (ja) * | 2013-12-03 | 2018-07-04 | 小林香料株式会社 | Hmbを含有する酸性飲料 |
| EP3082778B1 (en) | 2013-12-18 | 2019-04-03 | Capsugel Belgium NV | Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid |
| WO2015094767A1 (en) * | 2013-12-18 | 2015-06-25 | Abbott Laboratories | Methods for maintaining or increasing bodyweight using decaffeinated green tea extract |
| WO2015105981A2 (en) * | 2014-01-09 | 2015-07-16 | Abbott Laboratories | Conditional essentiality of hmb |
| CN118844612A (zh) * | 2014-03-14 | 2024-10-29 | 代谢科技有限公司 | 含有游离酸形式的β-羟基-β-甲基丁酸盐(HMB)的液体和食品 |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US20160184248A1 (en) * | 2014-12-15 | 2016-06-30 | University Of Central Florida Research Foundation Inc. | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response |
| ES2937282T3 (es) * | 2015-06-01 | 2023-03-27 | Metabolic Tech Llc | Composiciones y métodos de uso del beta-hidroxi-beta-metilbutirato (HMB) para disminuir la masa grasa |
| AU2016323779B2 (en) | 2015-09-16 | 2022-03-17 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| US12208073B2 (en) | 2015-09-16 | 2025-01-28 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| AU2017207910B2 (en) * | 2016-01-13 | 2022-09-01 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for joint stability |
| US11406609B2 (en) | 2016-01-21 | 2022-08-09 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy |
| CN121695115A (zh) * | 2016-01-21 | 2026-03-20 | 代谢科技有限责任公司 | β-羟基-β-甲基丁酸(HMB)用于调节自噬和噬脂的组合物和方法 |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| RU2018145520A (ru) | 2016-05-25 | 2020-06-25 | ТиЭсАй ГРУП ЛТД. | Стабилизация композиций бета-гидроксиизовалериановых кислот в мягких гелевых капсулах |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2018195067A1 (en) | 2017-04-17 | 2018-10-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| CN110868870A (zh) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | 大米产物及制备它们的系统和方法 |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CN108558707A (zh) * | 2018-04-13 | 2018-09-21 | 太仓运通新材料科技有限公司 | 一种三肌酸hmb盐的制备方法 |
| CA3090241C (en) * | 2018-04-25 | 2023-03-28 | Oncocross Co.,Ltd. | Composition for preventing and treating muscular disease |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| IL261670B (en) * | 2018-09-06 | 2019-06-30 | Tudu Holdings Ltd | Magnesium-containing formulation and uses thereof |
| MA50490A (fr) | 2018-09-24 | 2020-09-02 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| US10888576B2 (en) | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
| JP7286964B2 (ja) * | 2018-12-28 | 2023-06-06 | 日油株式会社 | β-ヒドロキシ-β-メチル酪酸、タンパク質、及び液状油脂を含有する液状栄養組成物 |
| CN111714616A (zh) * | 2019-07-17 | 2020-09-29 | 江苏西宏生物医药有限公司 | 一种用于抗肿瘤的组合物 |
| JP7594356B2 (ja) * | 2019-10-30 | 2024-12-04 | 小林製薬株式会社 | 経口組成物 |
| CA3160676A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| JP2023519170A (ja) * | 2020-03-12 | 2023-05-10 | アボット・ラボラトリーズ | 下痢または腸の炎症状態を治療する方法 |
| AU2021292308A1 (en) * | 2020-06-17 | 2023-02-09 | Metabolic Technologies, LLC | Compositions and methods of use of betaeta-hydroxy-betaeta-methylbutyrate (hmb) for improving muscle mass, strength and muscular function without exercise |
| CN116322685A (zh) | 2020-10-30 | 2023-06-23 | 雀巢产品有限公司 | 含有烟酰胺和维生素b6的组合物以及使用此类组合物来治疗恶病质或恶病质前期的方法 |
| CA3195509A1 (en) * | 2020-10-30 | 2022-05-05 | Pascal STUELSATZ | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for rehabilitation |
| WO2022090473A1 (en) * | 2020-10-30 | 2022-05-05 | Société des Produits Nestlé S.A. | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for promoting muscle growth |
| WO2022090458A1 (en) * | 2020-10-30 | 2022-05-05 | Société des Produits Nestlé S.A. | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating sarcopenia and frailty |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| US20250127743A1 (en) * | 2021-08-31 | 2025-04-24 | Institut National De Al Santé Et De La Recherche Médicale | Use of branched chain fatty acids (bcfas) for the treatment of intestinal inflammation |
| DE202023107635U1 (de) * | 2023-12-22 | 2024-02-08 | RenaCare NEPHROMED GmbH | Zusammensetzung zur Eiweißsubstitution |
| CN120837469B (zh) * | 2025-08-06 | 2026-05-08 | 中日友好医院(中日友好临床医学研究所) | β-羟基-β-甲基丁酸作为GSDMD的抑制剂及其抗细胞焦亡的应用 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US597650A (en) | 1898-01-18 | morris | ||
| US3408210A (en) * | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
| US3542560A (en) * | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
| GB1446965A (en) * | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
| US4104290A (en) * | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
| US4311645A (en) | 1980-03-24 | 1982-01-19 | Hoffmann-La Roche Inc. | Synthesis of SRS-active compounds |
| US4871768A (en) | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
| US4742081A (en) * | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
| US4866040A (en) | 1986-01-06 | 1989-09-12 | Alfred Stracher | Aminocarnitine directed pharmaceutical agents |
| DE3620433A1 (de) | 1986-06-18 | 1987-12-23 | Boehringer Ingelheim Kg | Verwendung von 2-(n-2,6-dichlorphenyl-n-allyl-amino)-imidazolin-(2) als cytoprotektives mittel |
| DE68904874T2 (de) | 1988-10-31 | 1993-07-15 | Sandoz Nutrition Ltd | Organische verbindungen. |
| US5000975A (en) * | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
| US5157022A (en) | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
| US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| US5167957A (en) * | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
| US5601860A (en) * | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
| FR2674102B1 (fr) | 1991-03-18 | 1994-05-20 | Meiji Seika Kaisha Ltd | Aliment pour porcs et methode d'elevage des porcs utilisant cet aliment. |
| US5085883A (en) | 1991-06-27 | 1992-02-04 | Abbott Laboratories | Blend of dietary fiber for nutritional products |
| US5171442A (en) * | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
| US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| JP3148243B2 (ja) * | 1992-09-16 | 2001-03-19 | アイオワ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | 総コレステロールおよび低密度リポタンパク質コレステロールの血中レベルを減少させる方法 |
| US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| US5348979A (en) * | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| DK0698078T3 (da) | 1993-05-13 | 1998-03-30 | Loders Croklaan Bv | Modermælks-fedtstoferstatninger fra interesteroficerede blandinger af triglycerider |
| US6136858A (en) * | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
| US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
| US5952314A (en) * | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
| US5444054A (en) * | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| KR0140248B1 (ko) | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
| DE19528461A1 (de) | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| ATE194264T1 (de) | 1995-12-15 | 2000-07-15 | Procter & Gamble | Getränke mit stabiler aroma-/trübungsemulsionen in anwesenheit von polyphosphate enthaltende konservierungssystemen und niedrigen gehalten an xanthangum |
| US6165518A (en) * | 1996-04-11 | 2000-12-26 | Loders Croklaan B.V. | Free flowing fat compositions |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US7504376B2 (en) * | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| DE29707308U1 (de) | 1997-04-23 | 1997-06-26 | Kunz, Armin, 66450 Bexbach | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
| US6660258B1 (en) * | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| US6103764A (en) * | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| US6194379B1 (en) | 1998-05-01 | 2001-02-27 | Abbott Laboratories | Elemental enteral formula |
| US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
| JP4175698B2 (ja) * | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| DE69923322T2 (de) | 1998-07-30 | 2005-12-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung |
| US5976550A (en) * | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
| US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
| JP3973786B2 (ja) | 1998-12-28 | 2007-09-12 | 松下電器産業株式会社 | スパッタリング方法及び装置 |
| US6294206B1 (en) * | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
| US6291525B1 (en) * | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
| AU784752B2 (en) * | 1999-10-18 | 2006-06-08 | Northern Innovations Holding Corp. | Food supplement for increasing lean mass and strength |
| GB9929919D0 (en) | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
| US6521591B1 (en) * | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
| US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| CA2404799C (en) | 2000-04-06 | 2007-08-07 | Conlinco, Inc. | Conjugated linoleic acid compositions |
| JP4625156B2 (ja) * | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20050106219A1 (en) * | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
| US6592878B2 (en) | 2000-08-03 | 2003-07-15 | North Carolina State University | Enhancement of development of oviparous species by in ovo feeding |
| EP1326502B1 (de) * | 2000-08-29 | 2005-05-18 | Lonza Ag | Verfahren zur herstellung einer granulierbaren mischung und carnitin-magnesium-hydroxycitrat |
| US20030203070A1 (en) * | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
| EP1198991B1 (en) * | 2000-10-20 | 2012-12-19 | Nutriz N.V: | Non-dairy products derived from rice |
| CN1457357A (zh) * | 2001-02-15 | 2003-11-19 | 旭电化工业株式会社 | 包含β-葡聚糖的制品 |
| JP3735070B2 (ja) * | 2001-03-26 | 2006-01-11 | 花王株式会社 | 容器詰乳化飲料 |
| US6620427B2 (en) * | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
| US20030021877A1 (en) * | 2001-06-13 | 2003-01-30 | Cain Frederick William | Micronised fat particles |
| DE10145818C1 (de) | 2001-09-17 | 2002-10-10 | Alfill Engineering Gmbh & Co K | Sterilisiervorrichtung mit H202-Verdampfer |
| GB2381451A (en) * | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
| JP2003137790A (ja) * | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−2,1(β2→β1)結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
| EP1453583B1 (en) * | 2001-12-12 | 2011-08-31 | Martek Biosciences Corporation | Extraction and winterization of lipids from biomass |
| DE10163676A1 (de) | 2001-12-21 | 2003-07-10 | Phenion Gmbh & Co Kg | Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose |
| US7168581B2 (en) * | 2001-12-21 | 2007-01-30 | Rexam Medical Packaging Inc. | Closure for a retort processed container having a peelable seal |
| US20030165579A1 (en) | 2002-02-27 | 2003-09-04 | Chih-Hui Lin | Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers |
| AU2003225131A1 (en) | 2002-04-23 | 2003-11-10 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors |
| SE0201581D0 (sv) * | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
| US20040013787A1 (en) * | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
| US20040048925A1 (en) * | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| US20040106678A1 (en) * | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
| US7411039B2 (en) * | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| US7332178B2 (en) * | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
| FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
| JP2008500271A (ja) * | 2003-10-14 | 2008-01-10 | ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン | 免疫介在性疾患の治療および/または予防におけるアデニル酸シクラーゼ |
| IL158555A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
| US8388949B2 (en) * | 2003-12-24 | 2013-03-05 | N.V. Nutricia | Compositions comprising pantothenic acid and their use for stimulating appetite |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20050249650A1 (en) * | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
| DE602005025510D1 (de) * | 2004-09-09 | 2011-02-03 | Nestec Sa | Herstellungsmethoden für nahrungsmittel mit verbesserter qualität |
| WO2006031699A2 (en) * | 2004-09-10 | 2006-03-23 | Diversa Corporation | Compositions and methods for making and modifying oils |
| PL371081A1 (pl) | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| US8067052B2 (en) * | 2005-02-25 | 2011-11-29 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
| CA2537452C (en) * | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
| KR101368603B1 (ko) * | 2005-04-27 | 2014-02-27 | 엔지모테크 리미티드 | 모유 지방 대체물 |
| KR20080015071A (ko) * | 2005-06-06 | 2008-02-18 | 브리스톨-마이어스스퀴브컴파니 | 저-피테이트 유아용 조제유 |
| CA2620366C (en) | 2005-08-26 | 2014-04-01 | Nestec S.A. | Nutrition for obese patients |
| MY147363A (en) * | 2005-09-20 | 2012-11-30 | Nestec Sa | Water dispersible composition and method for preparing same |
| EP1968402A2 (en) | 2005-10-07 | 2008-09-17 | Ocean Nutrition Canada Limited | Salts of fatty acids and methods of making and using thereof |
| US20080317886A1 (en) * | 2005-11-03 | 2008-12-25 | Sparkman Dennis R | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness |
| ES2548432T3 (es) * | 2005-12-19 | 2015-10-16 | Abbott Laboratories | Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2 |
| US20090087540A1 (en) * | 2006-01-31 | 2009-04-02 | Nestec S.A. | Nutritional composition for low birth weight infants |
| US20080119552A1 (en) * | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
| US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| CA2649477C (en) * | 2008-04-18 | 2016-04-19 | Nuvocare Health Sciences Inc. | Composition and method for promoting internal health and external appearance |
| MX2010012171A (es) | 2008-05-21 | 2010-11-30 | Stokely Van Camp Inc | Bebida de recupercion a base de leche. |
| DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
| JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
| US20090312419A1 (en) | 2009-08-12 | 2009-12-17 | Kneller Bruce W | CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
| PL217815B1 (pl) | 2009-12-14 | 2014-08-29 | Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością | Napój izotoniczny z chelatami |
| CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
| SG182812A1 (en) | 2010-01-29 | 2012-09-27 | Abbott Lab | Nutritional emulsions comprising calcium hmb |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
| US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
| EP2658535A1 (en) | 2010-12-27 | 2013-11-06 | Abbott Laboratories | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| WO2012097061A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| WO2013056048A2 (en) | 2011-10-13 | 2013-04-18 | Abbott Laboratories | Nutritional products comprising beta-alanine |
| WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
| US20150119339A1 (en) | 2012-06-11 | 2015-04-30 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
-
2004
- 2004-03-26 US US10/810,762 patent/US20050215640A1/en not_active Abandoned
- 2004-12-29 US US11/025,466 patent/US8217077B2/en not_active Expired - Fee Related
-
2005
- 2005-03-14 CA CA2807787A patent/CA2807787C/en not_active Expired - Lifetime
- 2005-03-14 JP JP2007504991A patent/JP5145033B2/ja not_active Expired - Fee Related
- 2005-03-14 EP EP10186645.7A patent/EP2301529B1/en not_active Expired - Lifetime
- 2005-03-14 AU AU2005235133A patent/AU2005235133B2/en not_active Ceased
- 2005-03-14 ES ES11187274T patent/ES2699161T3/es not_active Expired - Lifetime
- 2005-03-14 BR BRPI0509017-2A patent/BRPI0509017A/pt active Search and Examination
- 2005-03-14 CA CA2560042A patent/CA2560042C/en not_active Expired - Fee Related
- 2005-03-14 MX MXPA06010922A patent/MXPA06010922A/es active IP Right Grant
- 2005-03-14 CN CNA2005800095960A patent/CN101212961A/zh active Pending
- 2005-03-14 EP EP05732120A patent/EP1727534A2/en not_active Withdrawn
- 2005-03-14 KR KR1020067022383A patent/KR101253063B1/ko not_active Expired - Fee Related
- 2005-03-14 ES ES10186645.7T patent/ES2586402T3/es not_active Expired - Lifetime
- 2005-03-14 KR KR1020127033546A patent/KR20130010912A/ko not_active Ceased
- 2005-03-14 WO PCT/US2005/007951 patent/WO2005102301A2/en not_active Ceased
- 2005-03-14 EP EP11187274.3A patent/EP2444082B1/en not_active Expired - Lifetime
- 2005-03-25 TW TW094109357A patent/TWI369981B/zh not_active IP Right Cessation
-
2006
- 2006-09-12 IL IL178039A patent/IL178039A0/en unknown
- 2006-09-22 EC EC2006006873A patent/ECSP066873A/es unknown
-
2012
- 2012-01-11 US US13/347,877 patent/US8778993B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,956 patent/US8785495B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/348,024 patent/US8785496B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/348,035 patent/US8778994B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,985 patent/US20120177752A1/en not_active Abandoned
- 2012-01-11 US US13/348,026 patent/US8609725B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,978 patent/US20120189715A1/en not_active Abandoned
- 2012-06-21 JP JP2012139422A patent/JP5732437B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-09 JP JP2015045519A patent/JP2015147773A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11202798B2 (en) | Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution | |
| Serefko et al. | Magnesium in depression | |
| GB2596849A (en) | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual | |
| Liu et al. | Protective effect of vitamin E against acute kidney injury | |
| BRPI0509017A (pt) | composições hmb e utilizações das mesmas | |
| Hu et al. | Pyruvate-enriched oral rehydration solution improved intestinal absorption of water and sodium during enteral resuscitation in burns | |
| Harada et al. | Withdrawal: Preventive Effect of Morinda citrifolia Fruit Juice on Neuronal Damage Induced by Focal Ischemia | |
| Paulis et al. | Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study | |
| JPWO2002034257A1 (ja) | 中枢神経系の疲労回復又は予防剤及び疲労回復又は予防のための食品 | |
| RU2701720C1 (ru) | Комбинации пальмитоилэтаноламида для лечения хронической боли | |
| Mannis et al. | Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia | |
| Mikhaylovich et al. | Comparison of the effectiveness of various sulphur-containing hepatoprotectors against chronic alcoholization | |
| US20040091506A1 (en) | Topical antifungal treatment | |
| US11116246B2 (en) | Compositions of coenzyme Q10 and methods of use | |
| GT200600263A (es) | Regimen de dosificacion para prasugrel | |
| JPWO2006080086A1 (ja) | 中枢神経系の疲労回復又は疲労予防のための組成物 | |
| RU2698396C1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| Mychka et al. | Primary prophylaxis of cerebrovascular complications in patients with metabolic syndrome | |
| HU207800B (en) | Process for producing composition for improving condition and for treating different illnesses | |
| US20080200539A1 (en) | Topical antifungal treatment | |
| KR102965629B1 (ko) | 뇌혈관 질환 치료용 약물을 제조하는데 있어서의 실로스타졸-함유 조성물의 적용 | |
| RU2564907C1 (ru) | Способ лечения больных красным плоским лишаем | |
| CN109803547A (zh) | 含有脱辅基水母素和维生素d的组合物及其使用方法 | |
| RU2709502C1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| Nagkrishna et al. | Evaluation of protective effect of vitamin-e on vincristine induced peripheral neuropathy in albino rats |